PPARG and Parkinson disease: The protective effects of PPAR-γ agonists have been shown in many experimental models of brain injury, including cerebral ischemia (Shimazu et al. 2005; Chu et al. 2006; Pereira et al. 2006; Tureyen et al. 2007; Zhao et al. 2009; Kim et al. 2011), NMDA-induced cytotoxicity (Zhao et al. 2006, 2007), and Parkinson’s disease (Schintu et al. 2009; Ridder and Schwaninger 2012).